Time Trends of Perioperative Outcomes in Early-Stage Non-Small Cell Lung Cancer Resection Patients (Statistical Commentary)
Publication date: Available online 19 October 2019Source: The Annals of Thoracic SurgeryAuthor(s): Melanie P. Subramanian, Graham A. Colditz
ConclusionThe potential therapeutic value of fluzoparib for increasing the radiation sensitivity of NSCLC is well confirmed. Moreover, our findings of high mutation frequencies among HR genes suggest that PARP1 inhibition may be an effective treatment strategy for advanced non-small cell lung cancer patients.
The FDA recently granted priority review to Takeda ’s supplemental new drug application for brigatinib to treat ALK-positive metastatic non-small cell lung cancer.
Bioconjugate ChemistryDOI: 10.1021/acs.bioconjchem.9b00870
A BRAF V600E mutation is found as driver oncogene in patients with non-small cell lung cancer. Although combined treatment with dabrafenib and trametinib is highly effective, the efficacy of reduced doses of the ...
In recent years, treatment and prognosis for patients with metastatic non-small cell lung cancer (NSCLC) has changed profoundly due to introduction of immunotherapy. Blocking the programmed death-ligand 1 (PD-L1)/programmed death 1 (PD-1) pathway has become a new cornerstone in the treatment of advanced NSCLC patients, especially for those without targetable mutations. PD-L1 is mainly expressed by macrophages and endothelial cells, but also in a wide variety of solid tumors [1 –3]. Binding of PD-L1 to its receptor PD-1 on T cells or antigen presenting cells (APC) activates an inhibitory signal leading to apoptosis or...
Although immune checkpoint inhibitors (ICIs) have improved survival in many patients with non-small cell lung cancer (NSCLC),  our understanding of the safety and efficacy of these therapies in certain populations is limited. Patients with past2 or chronic  hepatitis B (HBV) or hepatitis C virus (HCV) infections, for example, have been excluded from most of the pivotal phase 3 immunotherapy clinical trials in lung cancer [1,2], so there is a paucity of data both on the risks of viral reactivation or flare, and on the rates of hepatotoxicity in these patients after treatment with ICIs.
Surgery may be underutilized for stage IIIA non-small cell lung cancer (NSCLC). Although an argument can be made for definitive chemoradiation (dCRT) for N2/3 mediastinal nodal disease, the role of a nonsurgical strategy is less clear in cT3N1M0 stage IIIA patients given a lack of randomized data. We therefore sought to determine outcomes of cT3N1M0 patients by treatment type from the National Cancer Database (NCDB).
AbstractPurposeStereotactic body radiotherapy (SBRT) is the primary treatment method for early-stage non-small cell lung cancer (NSCLC) considered inoperable due to medical comorbidities. However, the application of SBRT in patients aged ≥ 75 years has not been adequately studied. This retrospective study aimed to investigate the effectiveness and safety of SBRT in early-stage NSCLC patients aged ≥ 75 years, and the impact of treatment on nutritional status and self-care ability.MethodsHistopathologically confirmed early-stage (T1-3N0M0) NSCLC patients aged ≥ 7...
ConclusionNivolumab appeared to be safe and effective in Taiwanese patients. These interim results suggest that nivolumab is a suitable treatment option for this population.Clinical trial registrationNCT02582125.